Domestic-focused branded generics company selling diabetes, cardiac and dermatology drugs to Indian doctors and patients.
Domestic-focused branded generics company selling diabetes, cardiac and dermatology drugs to Indian doctors and patients.
Sells prescription brands in India that doctors recommend and pharmacies stock, so revenue relies on field sales teams building prescribing habits in long-term therapy areas such as diabetes and heart disease, and on buying brands from other companies. Founder Amit Bakshi leads the company.
In one line: A domestic-only Indian branded generics maker.
Moat: narrow (brand, distribution). Strong doctor-relationship-driven brand building in chronic therapy areas within India.
Headquarters: Ahmedabad, India · Founded: 2007 · Employees: 3,076
Size Eris Lifesciences (ERIS.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $1.98B, the 378th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹1,337 on 18 Nov 2026.
Performance Over six months the shares gained 0.1%, against -5.5% for the median peer and +3.8% for the India market (cap-weighted) — 10th highest of 21 in its peer set.
Growth Revenue grew 11.1% over the last twelve months (peer median +10.7%); the operating margin is 26.3% (peer median 20.9%).
Valuation It trades at 27.9× forward earnings against a peer median of 18.1× (6th most expensive of 18).
Price implies For today's price to make sense, revenue must grow about 26% a year for seven years (Req g). Recent delivered growth is +21%, so the hurdle is +5 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 1.7 points below its cost of capital (12.0% WACC).
Next results Next results expected around 22 Jan 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹33.3B | ₹31.3B | ₹28.9B | ₹20.1B | ₹16.9B |
| Revenue growth | — | +8% | +44% | +19% | — |
| Gross profit | ₹15.9B | ₹14.3B | ₹13.0B | ₹10.1B | ₹8.54B |
| EBITDA | ₹11.6B | ₹11.3B | ₹10.3B | ₹7.01B | ₹5.47B |
| Net income | ₹7.08B | ₹6.20B | ₹3.52B | ₹3.92B | ₹3.82B |
| Free cash flow | n/a | ₹542M | ₹7.73B | ₹2.87B | -₹5.69B |
| Capital expenditure | n/a | ₹2.97B | ₹1.55B | ₹1.29B | ₹8.41B |
| Total debt | ₹24.3B | ₹23.6B | ₹24.8B | ₹27.8B | ₹8.77B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Eris Lifesciences ERIS.NS | $1.98B | 0% | +11% | 26% | 27.9× | 26.3% |
| Mankind Pharma MANKIND.NS | $11.6B | +5% | +13% | 21% | 44.4× | 28.6% |
| Torrent Pharmaceuticals TORNTPHARM.NS | $18.8B | +3% | +42% | 22% | 70.2× | 37.6% |
| Alkem Laboratories ALKEM.NS | $6.69B | -5% | +13% | 17% | 27.3× | 25.0% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ERIS.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +19.3% | +0.3% | 2nd highest of 21 |
| 6-month return | +0.1% | -5.5% | 10th highest of 21 |
| Distance from 52-week high | -23.2% | -28.8% | 8th highest of 21 |
| Revenue growth (TTM) | +11.1% | +10.7% | 10th highest of 20 |
| Operating margin | 26.3% | 20.9% | 8th highest of 20 |
| Forward P/E | 27.9× | 18.1× | 6th most expensive of 18 |
| Growth the price implies (Req g, 7 yrs) | 26.3% | 1.7% | most demanding of 14 |
| Growth delivered (Del g) | +20.9% | +14.1% | 4th highest of 14 |
| Hurdle (Req g minus delivered) | +5.4 pp | -12.8 pp | 4th most demanding of 14 |
| ROIC minus cost of capital | -1.7 pp | +1.6 pp | 8th lowest of 20 |
| EV / EBITDA | 17.8× | 16.6× | 6th cheapest of 11 |
| Net debt / EBITDA | 1.9× | 0.7× | 3rd most indebted of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Eris Lifesciences ERIS.NS | India | $1.98B | 0% | +11% | 26% | 27.9× | 26.3% | +20.9% |
| InnoCare Pharma 9969.HK | Hong Kong | $2.01B | -10% | +146% | 35% | 32.2× | -2.0% | +341.1% |
| Hanall Biopharma 009420.KS | South Korea | $2.01B | +12% | +5% | 3% | n/a | n/a | n/a |
| Biohaven BHVN | United States | $1.95B | +46% | n/a | n/a | n/a | n/a | n/a |
| OneSource Specialty Pharma ONESOURCE.NS | India | $1.95B | -14% | +11% | 6% | 44.6× | n/a | n/a |
| Fujian Cosunter Pharmaceutical 300436.SZ | China | $2.02B | -45% | 0% | -47% | n/a | n/a | n/a |
| Harmony Biosciences HRMY | United States | $1.94B | +6% | +20% | 22% | 8.6× | -10.5% | +40.3% |
| Zhejiang Jiuzhou Pharmaceutical 603456.SS | China | $2.03B | +19% | -1% | 14% | 16.9× | 1.7% | +15.7% |
| Nanjing King-friend Biochemical Pharmaceutical 603707.SS | China | $2.03B | -3% | +9% | 14% | 25.9× | 5.1% | +6.4% |
| Jinyu Bio-Technology 600201.SS | China | $1.93B | -21% | +22% | 10% | 59.0× | 23.4% | -2.5% |
| Tsumura & 4540.T | Japan | $1.93B | +6% | +13% | 18% | 10.4× | n/a | n/a |
| Henan Lingrui Pharmaceutial 600285.SS | China | $2.04B | +9% | +5% | 22% | 15.9× | -4.7% | +10.6% |
| Grand Pharmaceutical 0512.HK | Hong Kong | $1.93B | -25% | +7% | 13% | 9.4× | 1.2% | +14.1% |
| Shilpa Medicare SHILPAMED.NS | India | $1.91B | +94% | +37% | 21% | 54.3× | n/a | n/a |
| Alivus Life Sciences ALIVUS.NS | India | $1.90B | +36% | +8% | 31% | 23.8× | 20.1% | +6.2% |
| Haw Par H02.SI | Singapore | $2.08B | -25% | -13% | 30% | 11.9× | 3.2% | +15.7% |
| Pfizer PFIZER.NS | India | $1.88B | -20% | +12% | 34% | 21.9× | 11.2% | +2.4% |
| Anhui Anke Biotechnology (Group) 300009.SZ | China | $1.88B | -12% | -9% | 30% | 18.1× | 8.0% | +9.3% |
| Tibet Rhodiola Pharmaceutical 600211.SS | China | $1.87B | -8% | +13% | 27% | 12.5× | -1.2% | +16.7% |
| PharmaResearch 214450.KS | South Korea | $2.10B | -24% | +29% | 37% | 15.4× | -11.0% | +37.6% |
| Cohance Lifesciences COHANCE.NS | India | $1.87B | +7% | +14% | 2% | 96.3× | n/a | n/a |